Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK
 

By selecting this, I agree to receive emails from celltelligence.com.


You will be granted access to your Celltelligence Library to view the full article after sign up.

Spotlight on Poseida’s CAR-T Strategy

Here is a brief preview of this blast: Since the first US CAR-T approval in 2017, the cell therapy field has rapidly evolved with 5 additional CAR-Ts receiving FDA approval. Nevertheless, challenges surrounding TATs, cost, and patient access still remain for autologous CAR-Ts. As such, off-the-shelf assets could be the answer to the industry’s current pain points. The Celltelligence team recently discussed with Eric Ostertag, Poseida’s Executive Chairman, the changing cell therapy landscape and how Poseida’s differentiated allogeneic platform could bring these life-changing therapies to a greater number of patients. Below, the Celltelligence team provides an analysis on Poseida’s allogeneic technology and how they could challenge key allogeneic and autologous competitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.